Drug Cost Strategy
Pharmacy Cost Containment
Pharmacy is now the fastest-growing cost driver in employer health plans. These are the strategies that actually move the needle — not cost-shifting, but structural reform.
What It Is
Pharmacy cost containment is the discipline of managing drug spend in an employer health plan through structural, contractual, and clinical interventions — rather than simply shifting costs to employees.
For self-funded employers, pharmacy is typically the second-largest line item after medical claims — and the fastest-growing. Unlike medical costs, pharmacy spend is highly transparent and highly manageable with the right tools and contracts.
Effective pharmacy cost containment requires understanding the full supply chain: drug manufacturers, wholesalers, pharmacy benefit managers (PBMs), retail and specialty pharmacies, and the plan's own formulary design. Each layer presents both risk and opportunity.
Key Concepts
Core Strategies
Formulary Optimization
A clinically driven formulary steers members to the most cost-effective drugs without sacrificing outcomes. Generic-first and therapeutic substitution policies are foundational.
Specialty Drug Management
Specialty drugs account for 50%+ of pharmacy spend for many plans. Specialty carve-outs, prior authorization, and step therapy protocols are essential controls.
Biosimilar Adoption
Biosimilars are FDA-approved alternatives to brand biologics, often at 20–40% lower cost. Formulary incentives and member education drive adoption.
Site-of-Care Optimization
Many infusion drugs administered in hospital outpatient settings cost 2–4× more than the same drug at a home infusion or physician office. Redirecting site of care generates immediate savings.
Manufacturer Assistance Programs
Patient assistance programs (PAPs) and copay assistance can offset member cost-sharing for high-cost specialty drugs — reducing plan spend when structured correctly.
Pharmacy Benefit Audit
An independent audit of PBM claims data verifies that pricing, rebates, and formulary management align with contract terms. Most audits uncover recoverable overpayments.
Why It Matters
For Employers
"Specialty drugs represent less than 2% of prescriptions but 50%+ of pharmacy spend for many self-funded plans."
"Employers who implement site-of-care programs for infusion drugs save an average of $15,000–$30,000 per redirected case."
"Biosimilar adoption rates in employer plans remain below 30% — leaving significant savings on the table."
Common Pitfalls
Mistakes to Avoid
- 1
Treating pharmacy as a fixed cost rather than a manageable variable with structural levers.
- 2
Relying on PBM rebate guarantees without understanding which drugs are included and how rebates are calculated.
- 3
Failing to implement prior authorization and step therapy for high-cost specialty drugs.
- 4
Not tracking site-of-care costs for infusion drugs separately from retail and specialty pharmacy.
- 5
Ignoring biosimilar adoption rates and failing to create formulary incentives that drive member behavior.
FAQ